Study looks at safety of imatinib, nilotinib for leukemia patients | Treatment-naive adult patients with HIV benefit from doravirine | Scientists identify 40 potential drug targets in multiple myeloma study
April 13, 2018
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Study looks at safety of imatinib, nilotinib for leukemia patients
Researchers evaluated outcomes of 11 patients with chronic myeloid leukemia who had no history of cardiovascular disease and been treated with either imatinib or nilotinib and had never been treated with tyrosine kinase inhibitors. The study in the journal Cardiovascular Toxicity found that treatment with imatinib or nilotinib for 12 months was not associated with reduced cardiovascular function.
Oncology Nurse Advisor online (4/9) 
LinkedIn Twitter Facebook Google+ Email
Registration open: FREE program in Kansas City, KS
Join us for a FREE Transfusion Science Educational Course (TSEC) in Kansas City, KS on May 17-18, 2018, presented by world renowned experts in transfusion medicine. Participants will receive 12 CEUs. Contact us at or call 833-835-3439.
Science & Health
Treatment-naive adult patients with HIV benefit from doravirine
A study comparing the doravirine and ritonavir-boosted darunavir in adult patients with HIV who were treatment-naive found that doravirine was just as effective as darunavir, with 84% of 383 patients in the doravirine group having plasma HIV-1 RNA less than 50 copies per mL versus 80% in the darunavir group. The findings were published in the journal The Lancet HIV last month.
Medscape (free registration)/Reuters (4/12) 
LinkedIn Twitter Facebook Google+ Email
Scientists identify 40 potential drug targets in multiple myeloma study
Scientists identify 40 potential drug targets in multiple myeloma study
(Tim Sloan/AFP/Getty Images)
Forty genes have been identified by investigators from London's Institute of Cancer Research that could become potential therapeutic targets. As reported in the journal Leukemia, the researchers were able to pinpoint coding and noncoding mutations linked to the development of multiple myeloma while examining whole-genome sequencing data from 765 patients.
GenomeWeb Daily News (free registration) (4/9) 
LinkedIn Twitter Facebook Google+ Email
Emerging Trends
CRISPR gene editing shows promise in early nonhuman primate studies
Early results of studies using CRISPR gene editing technology to cure diseases in monkeys are promising, particularly in diseases that involve mutation of a single gene, but most of the research has been on cells and healthy monkeys. The next step is for researchers to use gene editing to develop nonhuman primate models of specific diseases to generate real-world evidence that gene editing treatments are effective and safe before they are tried in humans.
MIT Technology Review online (free registration) (4/11) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
Wilson purchased by Alexion for $855M
Swedish biopharmaceutical firm Wilson Therapeutics was purchased by Alexion Pharmaceuticals for $855 million. Wilson has late-stage, orphan drug- and fast track-tagged WTX101, which is being developed to treat patients with Wilson disease.
Seeking Alpha (free registration) (4/11) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
New therapies recommended by Scottish regulator for NHS funding
The Scottish Medicines Consortium approved for National Health Service use Shire's Revestive, or teduglutide, for pediatric onset short bowel syndrome in children ages 1 to 17, and Sanofi's Kevzara, or sarilumab, for adults with rheumatoid arthritis who do not respond to or are intolerant of standard therapies. The regulator also endorsed two hepatitis C-targeting drugs: Gilead's Vosevi, or sofosbuvir/velpatasvir/voxilaprevir, which is indicated to treat certain adult patients with hepatitis C, and Gilead's Epclusa, or sofosbuvir-velpatasvir, for patients with hepatitis C genotype 1 or 4 infection.
PharmaTimes online (UK) (4/10) 
LinkedIn Twitter Facebook Google+ Email
Association News
AABB to host eCast on donor hemovigilance and DonorHART software
AABB will host an eCast, "Donor Hemovigilance: DonorHART Demo and Recent Findings," on Tuesday, April 17, at 2 p.m. Eastern Time. This program will provide listeners with a demonstration of the DonorHART software program and how facilities can compare their hemovigilance data with others. Speakers will also explore recent findings from the AABB Donor Hemovigilance Program.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Technical Director for Blood Bank
Biologist, Cell Product Development, GS-0401-12
Ignoring isn't the same as ignorance; you have to work at it.
Margaret Atwood,
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information